Oral Contraceptive Induced Hepatic Adenomas: Building a Biorepository
Study on Liver Tumors in Birth Control Users
Craig Lammert, MD
Primary Investigator
Brief description of study
Detailed description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Hepatic adenoma, Focal nodular hyperplasia, FNH
-
Age: 18 years or above
-
Gender: All
- Men and women ≥ 18 years with hepatic adenoma or FNH evident on CT or MRI imaging radiologic criteria
This study investigates why some women who take birth control pills develop rare liver tumors called hepatic adenomas. Hepatic adenomas are non-cancerous liver tumors. The study will collect samples like blood, saliva, and tissue from people with hepatic adenomas or focal nodular hyperplasia (FNH), which is another type of liver growth.
Participants will visit once to donate blood, saliva, and answer a questionnaire about their environment. Tissue samples will be taken if the adenoma or FNH is surgically removed. For those participating remotely, saliva samples will be collected using a mailed kit, and questionnaires will be completed online or by mail.
- Who can participate: Men and women aged 18 years or older with hepatic adenoma or FNH, identified through CT or MRI scans, can participate.
- Study details: Participants will provide blood and saliva samples and answer a questionnaire. Remote participants will send saliva samples by mail and complete surveys online or by mail.
- Study visits: The study requires 1 visit.